AI Article Synopsis
Article Abstract
Background: Older age and associated comorbid conditions increase the risk of severe form of COVID-19 and death. The SARS-CoV-2 vaccination campaign began in France in December 2020 targeting institutionalized older population before having been evaluated in this population. The objective of our study was to assess the tolerability of vaccination 21 days (D21) and 90 days after the first vaccination (D90) in institutionalized old people. Secondary objective was to assess its effectiveness (mortality, hospitalization and occurrence of COVID) at D21 and D90.
Methods: People living in nursing homes or in long-term hospitalization facilities in France were included 12-2020-06-2021. They were divided into SARS-CoV-2 vaccinated and unvaccinated groups. Vaccine tolerability was prospectively assessed by the occurrence of health events at D21 and D90 (local and systemic side effects, geriatric syndromes, cardiovascular events). Vaccine efficacy was assessed by the occurrence of COVID-19 and serious adverse events (unscheduled hospitalization and all-cause mortality).
Results: The mean age of the 2595 participants was 86 years, 83% received COVID-19 vaccine. There were no significant difference between the vaccinated and unvaccinated for systemic or local adverse events at D21 and D90. At D90, vaccinated participants had significantly fewer SARS-CoV-2 infections (odds ratio (95% confidence interval) = 0.35 (0.22-0.58)), fewer deaths or hospitalizations (0.50 (0.31-0.81)), fewer cardiovascular events (0.28 (0.12-0.64)) and fewer pressure ulcers (0.38 (0.17-0.88)).
Conclusions: In this prospective cohort study, COVID-19 vaccine in a very old institutionalized geriatric population had a reassuring safety profile and a protective effect on COVID-19, hospitalizations and deaths, cardiovascular events and pressure ulcers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s12877-024-05609-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Age-structured modeling of COVID-19 dynamics: the role of treatment and vaccination in controlling the pandemic.
J Math Biol
December 2024
Complex Systems Research Center, Shanxi University, Taiyuan, 030006, Shanxi, China.
In addition to non-pharmaceutical interventions, antiviral drugs and vaccination are considered as the optimal solutions to control and eliminate the COVID-19 pandemic. It is necessary to couple within-host and between-host models to investigate the impact of treatment and vaccination. Hence, we propose an age-structured model, where the infection age is used to link the within-host viral dynamics and the disease dynamics at the population level.
View Article and Find Full Text PDFBooster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults.
Front Immunol
December 2024
Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Age-associated differences in the effect of repetitive vaccination, particularly on memory T-cell and B-cell responses, remain unclear. While older adults (aged ≥65 years) exhibited enhanced IgG responses following COVID-19 mRNA booster vaccination, they produced fewer spike-specific circulating follicular helper T cells-1 than younger adults. Similarly, the cytotoxic CD8 T-cell response remained diminished with reduced PD-1 expression even after booster vaccination compared with that in younger adults, suggesting impaired memory T-cell activation in older adults.
View Article and Find Full Text PDFEditorial: Cross-reactive immunity and COVID-19.
Front Immunol
December 2024
Dpto de Immunologia, Facultad de Medicina, U. Complutense de Madrid, Madrid, Spain.
Development of a prediction nomogram for IgG levels among asymptomatic or mild patients with COVID-19.
Front Cell Infect Microbiol
December 2024
Department of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Objective: COVID-19 has evolved into a seasonal coronavirus disease, characterized by prolonged infection duration and repeated infections, significantly increasing the risk of patients developing long COVID. Our research focused on the immune responses in asymptomatic and mild cases, particularly the critical factors influencing serum immunoglobulin G (IgG) levels and their predictive value.
Methods: We conducted a retrospective analysis on data from 1939 asymptomatic or mildly symptomatic COVID-19 patients hospitalized between September 2022 and June 2023.
COVID-19 Pandemic and its Impact on Vaccine Hesitancy: A Review.
Oman Med J
July 2024
Postgraduate School of Molecular Medicine, Erasmus MC-University Medical Center, Rotterdam, The Netherlands.
Vaccination is one of the most successful public health initiatives in human history, significantly reducing the incidence and severity of infectious diseases. The success of any vaccination program depends on several factors, including effective leadership, funding, distribution management, and addressing vaccine hesitancy. Vaccine hesitancy, the delay or refusal to be vaccinated despite the availability of immunization services, has always been prevalent in societies but has become more pronounced during the COVID-19 pandemic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!